A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Trastuzumab Biosimilar ABP 980|DRUG: Pertuzumab
Sponsor: West German Study Group
Collaborators: Merck Sharp & Dohme LLC|NanoString Technologies, Inc.